BioNTech (NASDAQ:BNTX) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says

BioNTech (NASDAQ:BNTX) had its price target hoisted by Canaccord Genuity Group from $171.00 to $171.44 in a research note published on Wednesday morning,Benzinga reports. They currently have a buy rating on the stock.

BNTX has been the subject of a number of other research reports. HC Wainwright reaffirmed a “buy” rating and set a $150.00 price objective on shares of BioNTech in a report on Monday, November 18th. Deutsche Bank Aktiengesellschaft raised their price target on shares of BioNTech from $95.00 to $150.00 and gave the stock a “buy” rating in a research note on Thursday, September 19th. UBS Group upped their price objective on BioNTech from $97.00 to $131.00 and gave the company a “neutral” rating in a research note on Wednesday, September 18th. Evercore ISI upgraded BioNTech from an “in-line” rating to an “outperform” rating and raised their target price for the stock from $110.00 to $125.00 in a research report on Tuesday, November 19th. Finally, The Goldman Sachs Group upgraded BioNTech from a “neutral” rating to a “buy” rating and upped their price target for the company from $90.00 to $137.00 in a research report on Friday, November 8th. Four research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, BioNTech presently has a consensus rating of “Moderate Buy” and an average target price of $138.67.

BioNTech Stock Up 1.8 %

BNTX stock opened at $120.72 on Wednesday. BioNTech has a twelve month low of $76.53 and a twelve month high of $131.49. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The company has a market cap of $28.94 billion, a PE ratio of -57.48 and a beta of 0.26. The business’s 50-day simple moving average is $113.42 and its 200 day simple moving average is $98.19.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, topping the consensus estimate of ($1.26) by $2.07. The company had revenue of $1.24 billion for the quarter, compared to analyst estimates of $514.08 million. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. BioNTech’s revenue for the quarter was up 38.9% compared to the same quarter last year. During the same quarter last year, the firm earned $0.73 EPS. On average, research analysts anticipate that BioNTech will post -3.68 earnings per share for the current year.

Hedge Funds Weigh In On BioNTech

A number of large investors have recently modified their holdings of the stock. GAMMA Investing LLC raised its position in BioNTech by 86.9% in the 2nd quarter. GAMMA Investing LLC now owns 512 shares of the company’s stock worth $41,000 after purchasing an additional 238 shares during the last quarter. EverSource Wealth Advisors LLC raised its position in shares of BioNTech by 106.3% during the first quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock worth $43,000 after acquiring an additional 252 shares during the last quarter. Planning Capital Management Corp lifted its stake in shares of BioNTech by 45,000.0% during the third quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock valued at $54,000 after acquiring an additional 450 shares during the period. Blue Trust Inc. boosted its holdings in BioNTech by 491.1% in the third quarter. Blue Trust Inc. now owns 467 shares of the company’s stock valued at $55,000 after acquiring an additional 388 shares during the last quarter. Finally, Daiwa Securities Group Inc. boosted its holdings in BioNTech by 430.3% in the second quarter. Daiwa Securities Group Inc. now owns 1,925 shares of the company’s stock valued at $155,000 after acquiring an additional 1,562 shares during the last quarter. 15.52% of the stock is currently owned by institutional investors and hedge funds.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.